医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Announcement on Acquisition of the Right to Develop and Commercialize DE-105 from Santen Pharmaceutical Co., Ltd.

2015年04月27日 PM04:03
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ:4573)

This is to announce that R-Tech Ueno, Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO and President: Yukihiko Mashima, hereinafter referred to as “R-Tech Ueno”) has acquired the right to develop and commercialize DE-105 from Santen Pharmaceutical Co., Ltd. (Head Office: Kita-ku, Osaka, CEO and President: Akira Kurokawa, hereinafter referred to as “Santen”). DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing.

By acquisition of this right, R-Tech Ueno undertakes development of this agent towards commercialization going forward.

Moreover, we have also concluded an agreement with the inventor of DE-105, Professor Emeritus Teruo Nishida (Graduate School of Medicine, Yamaguchi University) to invite him as medical advisor of R-Tech Ueno. This arrangement enables us to promote development taking advantage of our strength; collaboration between industry and academia.

Our president Yukihiko Mashima, MD & PhD, who is also an ophthalmologist, made the following comments.
“DE-105 is an ophthalmic solution of neurotrophic factor peptide, discovered and developed from academia. It has been developed as a treatment for severe persistent corneal epithelial defects caused by corneal sensory nerve disorder (currently at the stage of Phase I clinical trial in the United States and Phase II clinical trial in Japan). Damage to corneal sensory nerves causes various corneal and conjunctival epithelial disorders (persistent corneal epithelial defects, post-LASIK corneal epithelial defects, severe dry eye, disorder associated with decreased corneal sensitivity caused by long-term contact lens wear, etc.); however, treatment utilizing existing ophthalmic solutions have not been satisfying treatments so far. Going forward, we will develop this agent as a curative treatment for various corneal and conjunctival epithelial disorders targeting at not only persistent corneal epithelial defects but also other diseases. The subject of acquisition this time not only includes the patents of DE-105 application in the fields of ophthalmology, dermatology, gastrointestinal medicine but also the right of development overseas as well as in Japan. In the U.S, Phase I clinical trial has already been completed, and we plan to actively undertake global development in collaboration with Professor Emeritus Teruo Nishida, who is the inventor of DE-105 and a global prominent clinical scientist.”

Potential effects of this arrangement on our business performance will be reflected in the earnings forecast for the fiscal year ending March 31, 2016.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/150427_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent